Trial Profile
Study of Omalizumab in chronic spontaneous urticaria
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2018
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- 30 Nov 2018 New trial record
- 01 Nov 2018 Results published in the Annals of Allergy, Asthma and Immunology